Compare Digital Realty Trust, Inc. (DLR) vs Cassava Sciences Inc (FLNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Digital Realty Trust, Inc. vs Cassava Sciences Inc — how do they compare? Digital Realty Trust, Inc. trades at $178.53 (market cap $65.32B), while Cassava Sciences Inc trades at $0.82 (market cap $39.40M). The key difference: Digital Realty Trust, Inc. is far larger — about 1657.9× Cassava Sciences Inc's market cap, and Digital Realty Trust, Inc. pays a 2.77% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Digital Realty Trust, Inc. for 93 Days and Cassava Sciences Inc for 37 Days on average.
| DLR | FLNA | |
|---|---|---|
Market Cap | $65.32B | $39.40M |
Volume | 2,563,950 | 759,018 |
Sector | Real Estate | Health |
52-Week High | $203.91 | $4.64 |
52-Week Low | $147.93 | $0.68 |
Typical Hold Time | 93 Days | 37 Days |
Enterprise Value | $84.03B | -$43.28M |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Digital Realty Trust (DLR) trades at $178.15, down 1.29% with a bearish technical outlook. The stock shows strong fundamentals with Q2 2026 EPS beating expectations at $1.21 versus $0.48 expected, and revenue growth from $6.11B in 2025 to projected $6.8B in 2026. Analyst consensus is strongly bullish with 34 buys and a $222.35 price target, supported by AI-driven data center demand and recent infrastructure expansions.
DLR presents a compelling growth opportunity driven by AI infrastructure demand, with record interconnection activity and strategic partnerships. Key risks include high valuation multiples (P/E 85.89) and significant capital expenditures. The technical bearish signal contrasts with strong fundamental momentum, creating potential for volatility near-term.
FLNA trades at $0.84, up 2.72% today, with a bearish technical signal despite recent earnings beats. The company shows negative profitability metrics with ROE at -55.79% and ROA at -35.34%, though valuation ratios like EV/EBITDA of 1.03 and P/B of 0.62 suggest potential undervaluation. Recent FDA clearance for epilepsy drug trials provides a positive catalyst, but negative cash flow trends and zero revenue remain concerns.
The outlook hinges on clinical trial success and revenue generation. Analyst consensus is bullish with 67% buy ratings, but high execution risk and cash burn require careful monitoring. Near-term catalysts include Phase 2a trial initiation in 2027, while financial sustainability remains the primary challenge for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Digital Realty Trust, Inc.
Digital Realty owns and operates nearly 300 data centers worldwide. It has more than 35 million rentable square feet across five continents. Digital's offerings range from retail co-location, where an enterprise may rent a single cabinet and rely on Digital to provide all the accommodations, to cold shells, where hyperscale cloud service providers can simply rent much, or all, of a barren, power-connected building. In recent years, Digital Realty has de-emphasized cold shells and now primarily provides higher-level service to tenants, which outsource their related IT needs to Digital. Digital Realty has also moved more into the co-location business, increasingly serving enterprises and facilitating network connections. Digital Realty operates as a real estate investment trust.
Read more on DLR →About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →
